Boron neutron capture therapy for locally recurrent head and neck squamous cell carcinoma : An analysis of dose response and survival

Show full item record



Permalink

http://hdl.handle.net/10138/305878

Citation

Koivunoro , H , Kankaanranta , L , Seppälä , T , Haapaniemi , A , Mäkitie , A & Joensuu , H 2019 , ' Boron neutron capture therapy for locally recurrent head and neck squamous cell carcinoma : An analysis of dose response and survival ' , Radiotherapy and Oncology , vol. 137 , pp. 153-158 . https://doi.org/10.1016/j.radonc.2019.04.033

Title: Boron neutron capture therapy for locally recurrent head and neck squamous cell carcinoma : An analysis of dose response and survival
Author: Koivunoro, Hanna; Kankaanranta, Leena; Seppälä, Tiina; Haapaniemi, Aaro; Mäkitie, Antti; Joensuu, Heikki
Contributor: University of Helsinki, Sauli Savolainen / Principal Investigator
University of Helsinki, University of Helsinki
University of Helsinki, HUS Comprehensive Cancer Center
University of Helsinki, HUS Head and Neck Center
University of Helsinki, HUS Head and Neck Center
University of Helsinki, University of Helsinki
Date: 2019-08
Language: eng
Number of pages: 6
Belongs to series: Radiotherapy and Oncology
ISSN: 0167-8140
URI: http://hdl.handle.net/10138/305878
Abstract: Background and purpose: Head and neck squamous cell carcinoma (HNSCC) that recurs locally is a therapeutic challenge. We investigated the efficacy of boron neutron capture therapy (BNCT) in the treatment of such patients and the factors associated with treatment response and survival. Methods and materials: Seventy-nine patients with inoperable, locally recurred HNSCC were treated with L-boronophenylalanine-mediated BNCT in Espoo, Finland, between February, 2003 and January, 2012. Prior treatments consisted of surgery and conventionally fractionated radiotherapy to a median cumulative dose of 66 Gy (interquartile range [IQR], 59-70 Gy) administered with or without concomitant chemotherapy. Tumor response was assessed using the RECISTv. 1.0 criteria. Results: Forty patients received BNCT once (on 1 day), and 39 twice. The median time between the 2 treatments was 6 weeks. Forty-seven (68%; 95% confidence interval [CI], 57-79%) of the 69 evaluable patients responded; 25 (36%) had a complete response, 22 (32%) a partial response, 17 (25%) a stable disease lasting for a median of 4.2 months, and 5 (7%) progressed. The patients treated with BNCT twice responded more often than those treated once. The median follow-up time after BNCT was 7.8 years. The 2-year locoregional progression-free survival rate was 38% and the overall survival rate 21%. A high minimum tumor dose and a small volume were independently associated with long survival in a multi-variable analysis. Conclusions: Most patients responded to BNCT. A high minimum tumor dose from BNCT was predictive for response and survival. (C) 2019 The Authors. Published by Elsevier B.V.
Subject: Boron neutron capture therapy
Head and neck cancer
Radiotherapy
Boronophenylalanine
STEREOTACTIC RADIOSURGERY
REIRRADIATION
CANCER
RADIOTHERAPY
TRIAL
IMRT
3126 Surgery, anesthesiology, intensive care, radiology
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0167814019303962_main.pdf 844.4Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record